Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scrip's stock tracker - April 2009

This article was originally published in Scrip

Executive Summary

The Scrip Stock Tracker for March ended with speculation as to the capital market impact of the G20 summit, and with a farewell to Genentech as a stand-alone company. April turned out to be an excellent month for the capital markets, with the emergence of a swine flu pandemic and concerns over the US government’s stress tests for the banks doing little to dent the feeling of optimism. With both the capital markets and economic indicators seeming to suggest that the worst may be over, it seems that the "green shoots" of recovery arrived as the outside world burst into spring. Independent healthcare consultant Emma Palmer Foster of EJ Palmer Consulting reviews the market performance of the sector's leading companies.

You may also be interested in...

Scrip's stock tracker - June 2009

As the year moves into summer, is the sun shining on the capital markets and in particular on the pharmaceutical and biotechnology sectors? In Scrip's Stock Tracker for June, Emma Palmer Foster of EJ Palmer Consulting examines these questions and some of the other trends within the life sciences sector.

Scrip's stock tracker - May 2009

The Scrip commentary on capital market sentiment, the Stock Tracker, was able to describe April in favourable terms, with references to green shoots and signs of optimism. The fragility of the recovery – if a recovery is indeed what it is – was emphasised in May, despite the main stock market indices still managing to put in a positive performance. The markets were highly volatile in the month, with defensive stocks in and out of favour, and commentators wondering whether the green shoots were real or imaginary. Independent healthcare consultant Emma Palmer Foster of EJ Palmer Consulting digs among the markets to find the story.

Executive Briefing - Financial innovation

How will the biopharmaceutical industry get through the capital crisis? In the face of unprecedented industry challenges, companies are stripping their businesses down to the essentials, showing increased flexibility and novelty in dealmaking, and concentrating on the medium term. Emma Palmer Foster weighs up the innovative survival strategies available to them


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts